Towards a new paradigm about hypertensive heart disease.
A new pathophysiologic paradigm on HHD is emerging. This entity is the result of the pathologic structural remodeling of the myocardium in response to a mosaic of hemodynamic and nonhemodynamic factors altered in hypertension more than just the adaptive hypertrophy of the left ventricular wall to increased pressure. The potential clinical relevance of this paradigm is given by the fact that it entails a new approach to HHD in terms of more detailed diagnosis and more demanding treatment. But this novel view of HHD may also have epidemiologic importance. In fact, the possibility that myocardial individuals prone to develop HHD may be detected before the appearance of clinical detectable LVH opens a new way to the prevention of cardiac complications associated with hypertension and its impact on the heart, namely heart failure.
Department of Cardiology and Cardiovascular Surgery, Molecular Cardiology Unit, School of Medicine, UniversityClinic, University of Navarra, Pamplona, Spain. jadimar@unav.es
Javier
J
Díez
D000959:Antihypertensive Agents / Q000627:therapeutic use; D017209:Apoptosis; D015415:Biomarkers; D005355:Fibrosis; D006439:Hemodynamics; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D017379:Hypertrophy, Left Ventricular / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology* / Q000517:prevention & control; D009206:Myocardium / Q000473:pathology; D032383:Myocytes, Cardiac / Q000473:pathology
D000959:Antihypertensive Agents; D015415:Biomarkers